Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention

被引：80

作者：

Garcia-Vidal, C. ^{[1
,2
]}

Rodriguez-Fernandez, S. ^{[2
]}

Teijon, S. ^{[2
]}

Esteve, M. ^{[3
]}

Rodriguez-Carballeira, M. ^{[2
]}

Lacasa, J. M. ^{[2
]}

Salvador, G. ^{[4
]}

Garau, J. ^{[2
]}

机构：

[1] Hosp Univ Bellvitge, Infect Dis Serv, Barcelona 08907, Spain

[2] Univ Barcelona, Hosp Mutua Terrassa, Serv Internal Med, Barcelona, Spain

[3] Univ Barcelona, Hosp Mutua Terrassa, Serv Gastroenterol, Barcelona, Spain

[4] Univ Barcelona, Hosp Mutua Terrassa, Serv Rheumatol, Barcelona, Spain

来源：

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES | 2009年 / 28卷 / 04期

关键词：

TUBERCULIN SKIN-TEST; NECROSIS-FACTOR ANTAGONISTS; FACTOR-ALPHA ANTAGONISTS; GAMMA RELEASE ASSAYS; RHEUMATOID-ARTHRITIS; LATENT TUBERCULOSIS; HEPATITIS-B; THERAPY; METHOTREXATE; REACTIVATION;

D O I：

10.1007/s10096-008-0628-x

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

We sought to determine factors associated with opportunistic infections (OI) in infliximab-treated patients. A retrospective study cohort (1999-2004) was examined. Nine OI were diagnosed in 94 infliximab-treated patients: tuberculosis (four), visceral leishmaniasis (one), pyogenic muscular abscess (one Salmonella spp. and one Streptococcus pneumoniae), and two viral infections (hepatitis B virus [HBV] and zoster ophthalmicus). The risk for OI was significantly higher in the first year of treatment (odds ratio [OR] 8; 95% confidence interval [CI] 2-50). Previous treatment with more than two immunosuppressive drugs was the only factor related to OI (OR 8.686; 95% CI 1.889-39.943). We identified the subset of patients treated with infliximab who had a higher risk for OI. The screening of latent infections is key to diminishing the incidence of these infections.

引用

页码：331 / 337

页数：7

共 50 条

[21] Infections during extracorporeal membrane oxygenation: epidemiology, risk factors, pathogenesis and prevention [J].

Biffi, Stefano ;

Di Bella, Stefano ;

Scaravilli, Vittorio ;

Peri, Anna Maria ;

Grasselli, Giacomo ;

Alagna, Laura ;

Pesenti, Antonio ;

Gori, Andrea .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2017, 50 (01) :9-16

[22] Opportunistic Infections, Mortality Risk, and Prevention Strategies in Patients With Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic (VEXAS) Syndrome [J].

Czech, Mary ;

Cuellar-Rodriguez, Jennifer ;

Patel, Bhavisha A. ;

Groarke, Emma M. ;

Cowen, Edward W. ;

Turturice, Benjamin ;

Beck, David B. ;

Wilson, Lorena ;

Goodspeed, Wendy ;

Darden, Ivana ;

Young, Neal S. ;

Hickstein, Dennis ;

Ombrello, Amanda ;

Hoffman, Patrycjia ;

Arikan, Evsen Apaydin ;

Sinaii, Ninet ;

Hathaway, Londa ;

Castelo-Soccio, Leslie ;

Fike, Alice ;

Kastner, Daniel B. ;

Grayson, Peter C. ;

Ferrada, Marcela A. .

OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (07)

[23] Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections [J].

Schneeweiss, S. ;

Korzenik, J. ;

Solomon, D. H. ;

Canning, C. ;

Lee, J. ;

Bressler, B. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 30 (03) :253-264

[24] Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data [J].

Simon, Teresa A. ;

Dong, Lixian ;

Winthrop, Kevin L. .

ARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)

[25] Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data [J].

Teresa A. Simon ;

Lixian Dong ;

Kevin L. Winthrop .

Arthritis Research & Therapy, 23

[26] Risk factors for infection in haematology patients treated with rituximab [J].

Kanbayashi, Yuko ;

Nomura, Kenichi ;

Fujimoto, Yoshiko ;

Yamashita, Mihoko ;

Ohshiro, Muneo ;

Okamoto, Kousuke ;

Matsumoto, Yosuke ;

Horiike, Shigeo ;

Takagi, Tatsuya ;

Ishida, Yoji ;

Taniwaki, Masafumi .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2009, 82 (01) :26-30

[27] Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab [J].

Heusele, Marion ;

Clerson, Pierre ;

Guery, Benoit ;

Lambert, Marc ;

Launay, David ;

Lefevre, Guillaume ;

Morell-Dubois, Sandrine ;

Maillard, Helene ;

Le Gouellec, Noemie ;

Hatron, Pierre-Yves ;

Hachulla, Eric .

CLINICAL RHEUMATOLOGY, 2014, 33 (06) :799-805

[28] Incidence of opportunistic infections in patients with rheumatoid arthritis treated with different molecular-targeted drugs: A population-based retrospective cohort study [J].

Takabayashi, Katsuhiko ;

Ando, Fumihiko ;

Ikeda, Kei ;

Nakajima, Hiroshi ;

Hanaoka, Hideki ;

Suzuki, Takahiro .

MODERN RHEUMATOLOGY, 2023, 33 (06) :1078-1086

[29] Tuberculosis and the risk of opportunistic infections and cancers in HIV-infected patients starting ART in Southern Africa [J].

Fenner, Lukas ;

Reid, Stewart E. ;

Fox, Matthew P. ;

Garone, Daniela ;

Wellington, Maureen ;

Prozesky, Hans ;

Zwahlen, Marcel ;

Schomaker, Michael ;

Wandeler, Gilles ;

Kancheya, Nzali ;

Boulle, Andrew ;

Wood, Robin ;

Henostroza, German ;

Egger, Matthias .

TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2013, 18 (02) :194-198

[30] Screening of adult dental patients visiting Khyber College of Dentistry, Peshawar for HBV and HCV infections and identifying the associated risk factors [J].

Haider, Jamila ;

Lufullah, Ghosia ;

Nazli, Rubina ;

Akhtar, Tasleem ;

Shah, Asma .

PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2017, 33 (03) :615-620

← 1 2 3 4 5 →